Welcome to our dedicated page for Talaris Therapeutics news (Ticker: tals), a resource for investors and traders seeking the latest updates and insights on Talaris Therapeutics stock.
Talaris Therapeutics, Inc. (Nasdaq: TALS) is a late-clinical stage biotechnology company based in Boston, MA, and Louisville, KY. Specializing in the development of transformative cell therapies, Talaris aims to alleviate the burden of chronic immunosuppression in organ transplant recipients and to induce durable remissions in patients with severe autoimmune and immune-mediated disorders. Founded on pioneering technology discovered by Dr. Suzanne Ildstad, Talaris operates its own cell processing facility in Louisville.
Recent Developments: Talaris recently announced the results of a special stockholder meeting held on October 17, 2023, where stockholders approved the issuance of shares to the stockholders of Tourmaline Bio, Inc. as part of a merger agreement. This merger, expected to close around October 19, 2023, will result in Tourmaline surviving as a direct wholly-owned subsidiary of Talaris. Post-merger, the combined company plans to operate under the name Tourmaline Bio, Inc., trading on Nasdaq under the new ticker symbol “TRML”.
In conjunction with the merger, Talaris will effect a 1-for-10 reverse stock split, reducing outstanding shares from approximately 42.8 million to about 4.28 million. Stockholders will receive cash payments for fractional shares. The reverse stock split will uniformly impact all holders and does not alter percentage ownership interests except for fractional shares.
Financial Condition & Partnerships: Talaris is supported by notable life sciences investors, including Blackstone Life Sciences, Longitude Capital, and Qiming Venture Partners USA. The merger with Tourmaline Bio will create a combined entity focusing on developing transformative medicines, with Tourmaline's lead program, TOUR006, targeting thyroid eye disease and atherosclerotic cardiovascular disease.
Talaris Therapeutics (Nasdaq: TALS), a late-stage cell therapy company, announces CEO Scott Requadt's presentation at the 2022 Cell & Gene Meeting on the Mesa, scheduled for October 11-13, 2022, in Carlsbad, California. This event will be livestreamed globally. A pre-recorded presentation will be available on-demand starting October 11. Talaris focuses on developing transformative therapies for solid organ transplantation and severe immune disorders, with corporate offices in Boston, a cell processing facility in Louisville, and research operations in Houston.
Talaris Therapeutics (Nasdaq: TALS), a late-stage cell therapy company, announced that its CEO, Scott Requadt, will present at William Blair’s Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event on September 28, 2022, at 1:00 PM ET. The presentation will focus on transforming the standard of care in solid organ transplantation and severe immune and blood disorders. A live webcast will be available on Talaris' website and archived for 30 days.
Talaris operates from Boston, MA, with facilities in Louisville, KY, and research in Houston, TX.
Talaris Therapeutics, Inc. (Nasdaq: TALS) announced participation in two key investor conferences. The first is the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 1:40 p.m. ET in New York. The second is the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 9:00 a.m. ET, also in New York. A live webcast of the presentations will be available on Talaris' investor website, with replays accessible post-event.
Talaris Therapeutics (TALS) reported significant developments from its Phase 3 FREEDOM-1 trial, indicating all patients treated with FCR001 post-transplant achieved >50% T-cell chimerism. Notably, those 12 months post-transplant have successfully discontinued anti-rejection drugs. The company presented at the American Transplant Congress 2022 and highlighted its solid cash position of $207.1 million, expected to last through 2024. However, R&D expenses rose to $13.2 million, contributing to a net loss of $18.1 million for Q2 2022.
Talaris Therapeutics provided an update on its Phase 3 FREEDOM-1 study of FCR001 in kidney transplant recipients. 22 donor-recipient pairs have been enrolled, with 7 patients successfully dosed. Notably, all 3 patients dosed over 12 months ago have been weaned off chronic anti-rejection drugs, maintaining stable kidney function. Additionally, all patients treated at least three months prior have shown >50% T-cell chimerism, a promising biomarker for tolerance. The company has updated its protocol to enhance GvHD prophylaxis following reported cases of low-grade acute graft-versus-host disease.
Talaris Therapeutics (TALS) presented new findings from its Phase 2 trial of FCR001 at the American Transplant Congress. A retrospective analysis shows FCR001-treated patients experienced improved kidney function and fewer cardiometabolic complications compared to those on immunosuppression over five years. Importantly, all patients weaned off immunosuppressants (IS) maintained their kidney without rejection. The FREEDOM-1 study update has been delayed and is rescheduled for June 30, 2022. This positions Talaris on a promising path in kidney transplantation therapy.
Talaris Therapeutics (TALS), a late-stage cell therapy company, announced plans to hold a conference call on June 8, 2022, at 8:00 a.m. ET. This call will provide updates on their presentations at the American Transplant Congress and data from the ongoing Phase 3 FREEDOM-1 study focused on living donor kidney transplant recipients. Investors can join via phone or webcast through Talaris’ website.
The company is dedicated to transforming care for solid organ transplants and severe immune disorders.
Talaris Therapeutics (Nasdaq: TALS) announced its participation in the Jefferies Healthcare Conference on June 8, 2022, at 10:30 AM ET in New York. CEO Scott Requadt will present during the event, highlighting the company's advancements in cell therapy for solid organ transplantation and severe immune disorders. A live webcast will be available on the Talaris website, with an archived version accessible for 30 days post-event. Talaris operates from Boston, MA, with a cell processing facility in Louisville, KY.
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-stage cell therapy company, announced that CEO Scott Requadt will present virtually at the H.C. Wainwright Global Investment Conference from May 23-25, 2022. The pre-recorded presentation will be available on May 24th at 7:00 AM ET on the Talaris website, where it will remain accessible for 90 days. Talaris is focused on developing transformative therapies for solid organ transplantation and severe immune and blood disorders, with corporate offices in Boston, a cell processing facility in Louisville, and research operations in Houston.
Talaris Therapeutics (Nasdaq: TALS) announced the appointment of Karen Smith, M.D., Ph.D., MBA, LLM as an independent director, effective May 17, 2022. Smith brings over 20 years of biopharmaceutical experience, having overseen 50+ clinical trials and more than 20 regulatory approvals. The company also reported the retirement of Nicholas Galakatos, Ph.D., a board member since 2018. This management change aims to strengthen Talaris’ leadership as it develops therapies for solid organ transplantation and immune disorders.
FAQ
What is the market cap of Talaris Therapeutics (tals)?
What does Talaris Therapeutics specialize in?
Where is Talaris Therapeutics based?
Who discovered the technology behind Talaris Therapeutics?
What recent developments have occurred at Talaris Therapeutics?
What is the significance of the reverse stock split for Talaris?
Who are the major investors backing Talaris Therapeutics?
What will be the focus of the combined company after the merger with Tourmaline?
What is TOUR006?
Will stockholders receive fractional shares after the reverse stock split?
Who should stockholders contact with questions about the reverse stock split?
